Supply Chain Director, Uquifa Group

Building Resilient, Transparent and Future-Ready Pharma Supply Chains Through ESG

ESG as a strategic lever

In the pharmaceutical industry, ESG has become a strategic tool to strengthen quality, supply continuity and customer trust. At UQUIFA, ESG is not only about compliance; it helps us anticipate risks, improve decision-making and build stronger long-term partnerships.

We integrate ESG into the qualification and monitoring of suppliers and external manufacturers. While quality, cost, availability and regulatory compliance remain essential, companies increasingly need partners that also demonstrate transparency, traceability, sustainability, technical reliability and ethical business practices.

Through tools such as our Third-Party Code of Conduct, ESG assessments and periodic reviews, we can identify risks, define improvement actions and prioritise suppliers that support sustainable growth.

Digitalisation, AI and expert judgement

Digitalisation is transforming supply chains by improving transparency, traceability and risk visibility. By connecting information across suppliers, materials, incidents, ESG performance and regulatory or logistical risks, companies can make faster and better-informed decisions.

At UQUIFA, AI already supports supplier segmentation and ESG risk assessment. It helps analyse documentation, identify risk signals and prioritise actions across our supplier base. However, AI remains a support tool. In a highly regulated industry such as pharma, decisions must always rely on reliable data, robust governance and expert judgement. Technology should enhance human expertise, not replace it.

Industrial innovation and environmental performance

Industrial innovation should improve not only productivity but also sustainability. In API and fine chemical manufacturing, automation, process monitoring, predictive maintenance and energy optimisation can reduce resource consumption, waste and emissions while improving operational efficiency.

Often, meaningful environmental improvements come from practical actions such as increasing yields, recovering materials, optimising cleaning processes and improving production planning. Sustainability is frequently driven by data, discipline and continuous improvement rather than large investments alone.

Circular economy with technical realism

The circular economy offers important opportunities for the pharmaceutical sector, but implementation must respect quality, safety, GMP requirements and regulatory expectations. Solvent recovery, waste valorisation, packaging reduction and logistics optimisation can deliver environmental benefits when supported by proper risk assessment and technical validation.

Success requires early collaboration between pharmaceutical companies, CDMOs, suppliers, quality and regulatory teams. Circularity should be approached as a shared objective that balances environmental ambition with technical and industrial feasibility.

Governance, Evidence and Accountability

Strong governance is essential for turning ESG commitments into measurable results. Policies must be supported by clear responsibilities, performance indicators, monitoring systems and corrective actions.

Today, stakeholders expect evidence rather than declarations. Metrics such as supplier assessments, corrective action plans, traceability, environmental performance and logistics-related emissions provide a more accurate picture of supply chain maturity. Integrating ESG with procurement, quality, compliance and operations strengthens both resilience and transparency.

Resilience, Geopolitics and Risk Prioritisation

ESG and resilience are increasingly interconnected. Climate events, geopolitical tensions, trade restrictions, logistics disruptions and governance failures can all affect access to raw materials, intermediates and critical services.

To reduce these risks, UQUIFA follows a dual approach. First, we qualify suppliers and manufacturers across different geographical regions to reduce dependency on single sources. Second, we use our own Risk Priority Number (RPN) methodology to classify suppliers according to factors such as criticality, location and other relevant risks.

This approach helps us prioritise actions, reduce vulnerabilities and develop alternatives before disruptions occur. In the pharmaceutical industry, anticipation is essential to protect quality, continuity of supply and customer confidence.

Strategic partners and cross-border collaboration

A strategic supplier is not defined only by capacity or price. It is a partner that demonstrates reliability, transparency, collaboration and a commitment to ESG principles.

Resilient supply chains are built through qualified and diversified supplier networks aligned with GMP and ESG standards. Regular assessments, performance monitoring, audits and shared objectives help strengthen these relationships.

Cross-border collaboration is equally important. Regulatory, logistical and sustainability challenges cannot be managed in isolation. Effective partnerships are based on trust, information sharing, technical expertise and a long-term perspective. The goal is not simply to expand the supplier network, but to improve its quality and reliability.

From fragmentation to integrated ESG leadership

One of the key lessons from other industries is that ESG cannot be managed as a standalone function. In pharma, sustainability must be integrated with quality, compliance, procurement, operations and digitalisation.

Looking towards 2030, ESG leadership will be defined by measurable results rather than extensive reporting. Leading organisations will rely on traceable data, risk-based supplier management, digital tools and multidisciplinary collaboration to improve resilience, efficiency and transparency.

The greatest challenge remains fragmentation. Companies that successfully connect ESG with core business decisions will be better positioned to respond to future risks and stakeholder expectations.

The evolving role of CDMOs

By 2030, CDMOs will play a broader strategic role within pharmaceutical supply chains. Beyond manufacturing, they will contribute to innovation, risk management, environmental performance and ESG objectives.

Key capabilities will include technical excellence, operational flexibility, digitalisation, supplier governance and collaboration on sustainability initiatives. The most successful CDMOs will demonstrate that resilience and sustainability are complementary goals that strengthen long-term competitiveness.

At UQUIFA, we are advancing in this direction by combining industrial expertise, ESG integration and proactive risk management to help build a more transparent, resilient and future-ready pharmaceutical supply chain.